Evidence map›Paper›PMID 35799329›Full record

ArticleStatistics in medicine2022

CAPITAL: Optimal subgroup identification via constrained policy tree search.

Hengrui Cai, Wenbin Lu, Rachel Marceau West, Devan V Mehrotra, Lingkang Huang

Open access · greenAbstract read
In one paragraph

Article in Statistics in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. SubgroupTE: Advancing Treatment Effect Estimation with Subgroup Identification.ACM transactions on intelligent systems and technology · 2025
    Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Hengrui CaiDepartment of Statistics, University of California Irvine, Irvine, California, USA.ORCID 0000-0002-5679-8862
Wenbin LuDepartment of Statistics, North Carolina State University, Raleigh, North Carolina, USA.ORCID 0000-0002-7320-4755
Rachel Marceau WestBiostatistics and Research Decision Sciences, Merck & Co., Inc., North Wales, Pennsylvania, USA.
Devan V MehrotraBiostatistics and Research Decision Sciences, Merck & Co., Inc., North Wales, Pennsylvania, USA.ORCID 0000-0002-0316-7362
Lingkang HuangBiostatistics and Research Decision Sciences, Merck & Co., Inc., Rahway, New Jersey, USA.
Decision Sciences (United States) · USNorth Carolina State University · USUniversity of California, Irvine · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Personalized medicine, a paradigm of medicine tailored to a patient's characteristics, is an increasingly attractive field in health care. An important goal of personalized medicine is to identify a subgroup of patients, based on baseline covariates, that benefits more from the targeted treatment than other comparative treatments. Most of the current subgroup identification methods only focus on obtaining a subgroup with an enhanced treatment effect without paying attention to subgroup size. Yet, a clinically meaningful subgroup learning approach should identify the maximum number of patients who can benefit from the better treatment. In this article, we present an optimal subgroup selection rule (SSR) that maximizes the number of selected patients, and in the meantime, achieves the pre-specified clinically meaningful mean outcome, such as the average treatment effect. We derive two equivalent theoretical forms of the optimal SSR based on the contrast function that describes the treatment-covariates interaction in the outcome. We further propose a constrained policy tree search algorithm (CAPITAL) to find the optimal SSR within the interpretable decision tree class. The proposed method is flexible to handle multiple constraints that penalize the inclusion of patients with negative treatment effects, and to address time to event data using the restricted mean survival time as the clinically interesting mean outcome. Extensive simulations, comparison studies, and real data applications are conducted to demonstrate the validity and utility of our method.

Indexed as

AlgorithmsPrecision MedicineHumansPolicyResearch Designconstrained policy tree searchoptimal subgroup identificationpersonalized medicine

Identifiers

PMID35799329
PMCPMC9544117
OpenAlexW3205129795

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.